Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

213 ta ish

Ish: Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett +37

    Maqola20172 iqtibos
    ABI

  2. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

    Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons +35

    Maqola20182 iqtibos
    ABI

  3. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

    Dana Stenger, Tanja A. Stief, Theresa Kaeuferle +12

    Maqola20202 iqtibos
    ABI

  4. Gene Editing and Genotoxicity: Targeting the Off-Targets

    Georges Blattner, Alessia Cavazza, Adrian J. Thrasher +1

    Sharh maqola20202 iqtibos
    ABI

  5. CRISPR activation and interference screens decode stimulation responses in primary human T cells

    Ralf Schmidt, Zachary Steinhart, Madeline Layeghi +6

    Maqola20222 iqtibos
    ABI

  6. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

    Sumin Jo, Shipra Das, Alan F. Williams +19

    Maqola20222 iqtibos
    ABI

  7. Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines

    Eugenia D. Namiot, Aleksandr V. Sokolov, Vladimir N. Chubarev +2

    Sharh maqola20232 iqtibos
    ABI

  8. Current Strategies for Exosome Cargo Loading and Targeting Delivery

    Haifeng Zeng, Shaoshen Guo, Xuancheng Ren +3

    Sharh maqola20232 iqtibos
    ABI

  9. The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods

    Yekta Metanat, Patrik Viktor, Ayesha Amajd +10

    Sharh maqola20242 iqtibos
    ABI

  10. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy

    Siheng Zhang, Linglong Peng, Yifei Chen +2

    Sharh maqola20242 iqtibos
    ABI

  11. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects

    Mehdi Alidadi, Haniyeh Barzgar, Mohammad Asif Zaman +4

    Sharh maqola20242 iqtibos
    ABI

  12. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>

    Karlo Perica, Nayan Jain, Michael Scordo +23

    Maqola20252 iqtibos
    ABI

  13. CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

    Paola Lanuti, Francesco Guardalupi, Giulia Corradi +32

    Maqola20252 iqtibos
    ABI

  14. Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies

    Ahmed Ismail, Mohsen A. Khormi, Wedad Mawkili +6

    Sharh maqola20252 iqtibos
    ABI

  15. Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells

    Yasmeen A. Albalawi

    Sharh maqola20252 iqtibos
    ABI

  16. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI